米力农治疗顽固性充血性心力衰竭的疗效分析

目的观察米力农治疗顽固性充血性心力衰竭(CHF)的临床疗效。方法选择2009年6月—2013年5月在我院住院的顽固性CHF患者96例,根据治疗方法将所有患者分为试验组48例和对照组48例。两组患者均进行常规治疗,对照组加用多巴酚丁胺,试验组加用米力农。观察两组患者治疗前后N末端脑钠肽前体(NT-proBNP)、左室射血分数(LVEF)、短轴缩短率(FS)、心脏每搏输出量(SV)及心输出量(CO)。结果治疗前两组患者NT-proBNP、LVEF、FS、SV、CO比较,差异均无统计学意义(P0.05);治疗后试验组患者NT-proBNP低于对照组,LVEF、FS、SV、CO高于对照组(P0.05)。与治疗前比较,对照组和试验组NT-proBNP均降低,LVEF、CO均升高,试验组FS、SV均升高(P0.05)。结论米力农治疗顽固性CHF安全有效,值得在基层医院推广。

Efficacy of Milrinone on Intractable Congestive Heart Failure

Objective To observe the efficacy of milrinone on intractable congestive heart failure（CHF）. Methods From June 2009 to May 2013,a total of 96 patients with intractable CHF in our hospital were randomly divided into control group and test group,each of 48 cases. Both groups given conventional treatment,and control group given dobutamine,test group given milrinone on the basis of conventional treatment. The N - terminal pro - brain natriuretic peptide（NT - proBNP）, left ventricular ejection fraction（ LVEF）,fraction shortening（ FS）,stroke volume（ SV） and cardiac output（ CO）were compared between the two groups. Results Before treatment,there was no significant differences of NT - proBNP,LVEF, FS,SV,CO between the two groups（P 〉 0. 05）;after treatment,the NT - proBNP was lower in test group than that in control group（P 〈 0. 05）,while LVEF,FS,SV,CO higher. The NT - proBNP after treatment was lower,LVEF and CO higher in both groups when compared to those before treatment,and FS,SV only in test group were higher（P 〈 0. 05）. Conclusion Milrinone is safe and effective in the treatment of intractable CHF,and is worthy of promotion in primary hospitals.